Inhibikase Therapeutics, Inc. (IKT) Operating Margin % [USD] 2020 - 2024

Historical data

Taxonomy & unit
ratio: %
Description
The operating margin measures the profit a company makes on a dollar of sales after accounting for the direct costs involved in earning those revenues.
Summary
Inhibikase Therapeutics, Inc. quarterly/annual Operating Margin history and growth rate from 2020 to 2024.
  • Inhibikase Therapeutics, Inc. Operating Margin for the quarter ending March 31, 2024 was -10.3 K %, a 19.8% increase year-over-year.
  • Inhibikase Therapeutics, Inc. annual Operating Margin for 2023 was -7.71 K %, a 47.5% increase from 2022.
  • Inhibikase Therapeutics, Inc. annual Operating Margin for 2022 was -14.7 K %, a 2984% decline from 2021.
  • Inhibikase Therapeutics, Inc. annual Operating Margin for 2021 was -476 %, a 18% decline from 2020.
Operating Margin, Quarterly (% [USD])
Operating Margin, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Start Date End Date
Q1 2024 -10.3 K +2.54 K +19.8% Jan 1, 2024 Mar 31, 2024
Q4 2023 -7.71 K +6.97 K +47.5% Oct 1, 2023 Dec 31, 2023
Q3 2023 -6.18 K +24.3 K +79.7% Jul 1, 2023 Sep 30, 2023
Q2 2023 -7.85 K -2.94 K -60% Apr 1, 2023 Jun 30, 2023
Q1 2023 -12.8 K -11.9 K -1229% Jan 1, 2023 Mar 31, 2023
Q4 2022 -14.7 K -14.2 K -2984% Oct 1, 2022 Dec 31, 2022
Q3 2022 -30.5 K -30.1 K -9017% Jul 1, 2022 Sep 30, 2022
Q2 2022 -4.91 K -4.67 K -1953% Apr 1, 2022 Jun 30, 2022
Q1 2022 -965 -697 -261% Jan 1, 2022 Mar 31, 2022
Q4 2021 -476 -72.7 -18% Oct 1, 2021 Dec 31, 2021
Q3 2021 -334 Jul 1, 2021 Sep 30, 2021
Q2 2021 -239 Apr 1, 2021 Jun 30, 2021
Q1 2021 -267 Jan 1, 2021 Mar 31, 2021
Q4 2020 -404 Oct 1, 2020 Dec 31, 2020
* An asterisk sign (*) next to the value indicates that the value is likely invalid.